Wednesday, May 27, 2015 1:54:47 PM
http://campaign.r20.constantcontact.com/render?ca=1ba7aebc-e835-4753-9a50-090cc0de0a10&c=a605dc10-4eb0-11e4-b0b7-d4ae5292bb50&ch=a609fac0-4eb0-11e4-b0b7-d4ae5292bb50
May 27, 2015 NASDAQ:NWBO
Dear Jim,
Wanted to call your attention to the attached release from this morning providing the details of NW Bio's upcoming presentation this weekend in Chicago, on the survival data to date and other findings of the DCVax-Direct Phase I/II Trial for all types of inoperable solid tumors.
Hope you can tune in to the live webcast and hear about this new DCVax-Direct information.
Sincerely,
Leslie J. Goldman
Senior Vice President for Business Development
Embargoed for Release On Wednesday, May 27, 2015, at 8:30 a.m.
NW BIO TO PRESENT OVERVIEW OF DCVAX-DIRECT PHASE I TRIAL
IN CHICAGO THIS WEEKEND
Will Include Survival Data To Date and Other Findings
BETHESDA, MD, May 27, 2015 - Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix L. Bosch, Chief Technical Officer of the Company, will be making an Industry Expert Theater Presentation at the 2015 ASCO Annual Meeting in Chicago on Saturday, May 30, 2015, from 3 to 4 p.m. CDT, at the Industry Expert Theater in McCormick Place.
Dr. Bosch will provide an overview of the Company's DCVax-Direct Phase I trial, including new information about survival data collected to date and other findings. Dr. Bosch will also discuss these other findings in connection with the Company's plans for DCVax-Direct Phase II trials.
Dr. Bosch's presentation will be webcast live at nwbio.com/webcast
Not an official presentation of the 2015 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation. Not CME-accredited.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM